Cargando…
The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with pot...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165314/ https://www.ncbi.nlm.nih.gov/pubmed/30065158 http://dx.doi.org/10.3390/medicines5030081 |
_version_ | 1783359807655247872 |
---|---|
author | Tavares, Wilson R. Seca, Ana M. L. |
author_facet | Tavares, Wilson R. Seca, Ana M. L. |
author_sort | Tavares, Wilson R. |
collection | PubMed |
description | Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with potential for development of new drugs. Methods: The research for this review were based in the Scopus and Web of Science databases using terms combining Juniperus, secondary metabolites names, and biological activities. This is not an exhaustive review of Juniperus compounds with biological activities, but rather a critical selection taking into account the following criteria: (i) studies involving the most recent methodologies for quantitative evaluation of biological activities; and (ii) the compounds with the highest number of studies published in the last four years. Results: From Juniperus species, several diterpenes, flavonoids, and one lignan were emphasized taking into account their level of activity against several targets. Antitumor activity is by far the most studied, being followed by antibacterial and antiviral activities. Deoxypodophyllotoxin and one dehydroabietic acid derivative appears to be the most promising lead compounds. Conclusions: This review demonstrates the Juniperus species value as a source of secondary metabolites with relevant pharmaceutical potential. |
format | Online Article Text |
id | pubmed-6165314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61653142018-10-10 The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites Tavares, Wilson R. Seca, Ana M. L. Medicines (Basel) Review Background: Plants and their derived natural compounds possess various biological and therapeutic properties, which turns them into an increasing topic of interest and research. Juniperus genus is diverse in species, with several traditional medicines reported, and rich in natural compounds with potential for development of new drugs. Methods: The research for this review were based in the Scopus and Web of Science databases using terms combining Juniperus, secondary metabolites names, and biological activities. This is not an exhaustive review of Juniperus compounds with biological activities, but rather a critical selection taking into account the following criteria: (i) studies involving the most recent methodologies for quantitative evaluation of biological activities; and (ii) the compounds with the highest number of studies published in the last four years. Results: From Juniperus species, several diterpenes, flavonoids, and one lignan were emphasized taking into account their level of activity against several targets. Antitumor activity is by far the most studied, being followed by antibacterial and antiviral activities. Deoxypodophyllotoxin and one dehydroabietic acid derivative appears to be the most promising lead compounds. Conclusions: This review demonstrates the Juniperus species value as a source of secondary metabolites with relevant pharmaceutical potential. MDPI 2018-07-31 /pmc/articles/PMC6165314/ /pubmed/30065158 http://dx.doi.org/10.3390/medicines5030081 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tavares, Wilson R. Seca, Ana M. L. The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title | The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title_full | The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title_fullStr | The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title_full_unstemmed | The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title_short | The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites |
title_sort | current status of the pharmaceutical potential of juniperus l. metabolites |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165314/ https://www.ncbi.nlm.nih.gov/pubmed/30065158 http://dx.doi.org/10.3390/medicines5030081 |
work_keys_str_mv | AT tavareswilsonr thecurrentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites AT secaanaml thecurrentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites AT tavareswilsonr currentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites AT secaanaml currentstatusofthepharmaceuticalpotentialofjuniperuslmetabolites |